This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
Centene's Operations Improve: Does the 12.34X P/E Make it a Buy?
by Kaibalya Pravo Dey
CNC's improving Medicaid margins, stronger Marketplace profitability and earnings recovery support its valuation, but sustainability remains the key test.
CNCNegative Net Change UNHNegative Net Change ELVNegative Net Change
healthcare hmo insurance medical
Encompass Health Expands Rehab Footprint With New Maine Hospital
by Zacks Equity Research
EHC opens a 50-bed Maine rehab hospital, expanding its footprint as strong discharge growth and planned openings support capacity expansion.
EHCPositive Net Change PAHCNegative Net Change WGSNegative Net Change CONPositive Net Change
medical smart-health
BDX Expands U.S. Manufacturing With $19B Healthcare Investment
by Zacks Equity Research
BD plans a $19B U.S. investment, including $3B for manufacturing, to boost domestic medical consumables capacity and supply-chain resilience.
BDXPositive Net Change WSTNegative Net Change OPKNegative Net Change GMEDNegative Net Change
medical medical-devices
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
by Zacks Equity Research
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
BBIONegative Net Change BMRNNegative Net Change ASNDNegative Net Change
biotechs medical
Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?
by Debanjana Dey
ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.
ELTPPositive Net Change AYTUNo Net Change
biotechnology biotechs medical pharmaceuticals
Do Options Traders Know Something About Viemed Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to VMD stock based on the movements in the options market lately.
VMDPositive Net Change
medical medical-devices
Is the Options Market Predicting a Spike in Integer Holdings Stock?
by Zacks Equity Research
Investors need to pay close attention to ITGR stock based on the movements in the options market lately.
ITGRPositive Net Change
medical
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3?
by Kanishka Das
IRWD's Linzess demand remains strong, with a recent pediatric label expansion and pricing changes poised to support third-quarter 2026 growth.
IRWDPositive Net Change AZNNegative Net Change ABBVPositive Net Change
medical
Are Options Traders Betting on a Big Move in Grifols Stock?
by Zacks Equity Research
Investors need to pay close attention to GRFS stock based on the movements in the options market lately.
GRFSNegative Net Change
medical
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
by Zacks Equity Research
HQY's strong HSA growth, AI-driven efficiencies and raised fiscal 2027 outlook support momentum, though cybersecurity risks remain a concern.
HQYPositive Net Change WSTNegative Net Change GMEDNegative Net Change VCYTPositive Net Change
medical medical-devices